Health care professionals have a responsibility to educate patients about public screening programs and ensure that subsequent follow-up is done after the screening is completed.
Physicians should encourage pharmaceutical companies to make socially responsible funding decisions and take an active role in setting biomedical research priorities by advocating for fair and effective allocations of public and private biomedical R & D investments.